Intervacc AB (publ) (FRA:2E9)

Market Cap	33.01M +1.6%
Revenue (ttm)	1.64M -0.7%
Net Income	-8.29M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0769
Previous Close	0.0792
Day's Range	0.0769 - 0.0769
52-Week Range	0.0067 - 0.1118
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E9

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error